Issue №024 · The GLP-1 Quarterly
The price of thinness,
measured weekly.
An independent index of every GLP-1 receptor agonist on the U.S. market — what they cost, what they do, where to find them, and which ones your insurance will actually pay for. Updated weekly from FDA, Medicare, and pharmacy data.
Drugs Tracked
04
FDA approved · Q4 2024
Pharmacies Indexed
62,000+
U.S. retail network
Insurance Plans
148
Commercial + Medicare
Avg. monthly cost
$1,118
Cash · pre-coupons
§ 01 · Live Board
The Big Four
Cash price / 28-day supply · USD
Novo Nordisk
Ozempic
Semaglutide
$968.52
Approved2017
IndicationType 2 Diabetes
Avg. weight loss14.9%
Statusavailable
Novo Nordisk
Wegovy
Semaglutide
$1,349.02
Approved2021
IndicationChronic weight management
Avg. weight loss16.9%
Statuslimited
Eli Lilly
Mounjaro
Tirzepatide
$1,069.08
Approved2022
IndicationType 2 Diabetes
Avg. weight loss20.9%
Statusavailable
Eli Lilly
Zepbound
Tirzepatide
$1,086.37
Approved2023
IndicationChronic weight management
Avg. weight loss22.5%
Statusavailable
§ Index of Sections
Six tools, no logins, no upsells.
§ 02
Compare
Side-by-side: efficacy, dosage, mechanism.
§ 03
Pharmacies
Cash price by major chain — sortable.
§ 04
Insurance
Coverage matrix across major insurers.
§ 05
Side Effects
Trial-data percentages, drug by drug.
§ 06
Shortage
FDA supply status & 12-month history.
§ 07
Telehealth
Eight providers, vetted and ranked.
§ Primer
What, exactly, is a GLP-1?
Glucagon-like peptide-1 receptor agonists mimic an intestinal hormone that signals satiety, slows gastric emptying, and stimulates insulin. Originally built for type-2 diabetes, they became the most-prescribed weight-loss class in modern medicine within four years.
- Class
- Incretin mimetic
- Route
- Subcutaneous
- Frequency
- Once weekly
- Half-life
- ~7 days
- Discovered
- 1980s
- First Rx
- 2005 (Byetta)
1 in 8
U.S. adults have used a GLP-1
$71B
Projected GLP-1 market by 2032
−15%
Avg. weight loss · 68 weeks · semaglutide
≥12 mo
Recommended duration of therapy